Barclays Analysts Give Teva Pharmaceutical Industries (TEVA) a $20.00 Price Target

Barclays set a $20.00 price objective on Teva Pharmaceutical Industries (NYSE:TEVA) in a research note released on Thursday, Marketbeat reports. The firm currently has a hold rating on the stock.

A number of other research firms have also recently issued reports on TEVA. Oppenheimer reissued a hold rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, February 8th. Royal Bank of Canada raised Teva Pharmaceutical Industries from an underperform rating to a sector perform rating and set a $18.00 price objective for the company in a research report on Friday, February 9th. ValuEngine raised Teva Pharmaceutical Industries from a buy rating to a strong-buy rating in a research report on Monday, April 2nd. Cantor Fitzgerald set a $18.00 price objective on Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Thursday, May 3rd. Finally, Maxim Group reissued a hold rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, May 3rd. Ten equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and six have issued a buy rating to the stock. Teva Pharmaceutical Industries currently has an average rating of Hold and a consensus price target of $19.86.

TEVA opened at $22.18 on Thursday. The firm has a market cap of $22.00 billion, a P/E ratio of 5.64, a PEG ratio of 1.77 and a beta of 0.67. Teva Pharmaceutical Industries has a 1 year low of $10.85 and a 1 year high of $33.82. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 1.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Thursday, May 3rd. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.28. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.80 billion. Teva Pharmaceutical Industries had a positive return on equity of 18.59% and a negative net margin of 72.36%. The business’s revenue for the quarter was down 10.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.06 earnings per share. analysts predict that Teva Pharmaceutical Industries will post 2.45 earnings per share for the current year.

In other Teva Pharmaceutical Industries news, Director Roberto Mignone acquired 750,000 shares of the company’s stock in a transaction dated Thursday, May 10th. The shares were acquired at an average cost of $19.24 per share, for a total transaction of $14,430,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 5,684 shares of company stock worth $105,411 over the last quarter. 0.43% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the company. Wetherby Asset Management Inc. increased its stake in Teva Pharmaceutical Industries by 27.5% during the first quarter. Wetherby Asset Management Inc. now owns 13,265 shares of the company’s stock valued at $227,000 after acquiring an additional 2,857 shares during the period. IFM Investors Pty Ltd increased its stake in Teva Pharmaceutical Industries by 12.2% during the first quarter. IFM Investors Pty Ltd now owns 28,340 shares of the company’s stock valued at $484,000 after acquiring an additional 3,089 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Teva Pharmaceutical Industries by 1.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 198,178 shares of the company’s stock valued at $3,755,000 after acquiring an additional 3,100 shares during the period. Hanson & Doremus Investment Management increased its stake in Teva Pharmaceutical Industries by 7.4% during the first quarter. Hanson & Doremus Investment Management now owns 48,448 shares of the company’s stock valued at $828,000 after acquiring an additional 3,358 shares during the period. Finally, WealthTrust Axiom LLC increased its stake in Teva Pharmaceutical Industries by 29.9% during the fourth quarter. WealthTrust Axiom LLC now owns 14,948 shares of the company’s stock valued at $283,000 after acquiring an additional 3,440 shares during the period. Institutional investors and hedge funds own 64.73% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply